Trevi Therapeutics, Inc. Payments of Financing Costs
Trevi Therapeutics, Inc. (TRVI) reported Payments of Financing Costs of $21.00 thousand for the 12-month period ending 2022-12-31, per its 10-K filed 2024-03-20.
Discontinued › Cash Flow › Financing Activities
us-gaap:PaymentsOfFinancingCosts · last filed 2024-03-20
- Trevi Therapeutics, Inc. payments of financing costs for the quarter ending 2022-12-31 was $0.00.
- Trevi Therapeutics, Inc. payments of financing costs for the quarter ending 2022-09-30 was $0.00.
- Trevi Therapeutics, Inc. payments of financing costs for the quarter ending 2021-12-31 was $0.00, a 100.00% decline year-over-year.
- Trevi Therapeutics, Inc. payments of financing costs for the quarter ending 2020-12-31 was $31.00K.
- Trevi Therapeutics, Inc. payments of financing costs for fiscal 2022 was $21.00K, a 69.12% decline from fiscal 2021.
- Trevi Therapeutics, Inc. payments of financing costs for fiscal 2021 was $68.00K, a 19.05% decline from fiscal 2020.
- Trevi Therapeutics, Inc. payments of financing costs for fiscal 2020 was $84.00K.
| Period end | Payments of Financing Costs 3 month | Payments of Financing Costs 6 month | Payments of Financing Costs 9 month | Payments of Financing Costs 12 month |
|---|---|---|---|---|
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-20 | $0.00 derived: sum of 2 quarters · filed 2024-03-20 | $21.00K 10-K · filed 2024-03-20 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $21.00K 10-Q · filed 2023-11-09 | ||
| 2022-06-30 | $21.00K 10-Q · filed 2023-08-10 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $68.00K 10-K · filed 2023-03-16 | ||
| 2021-09-30 | $68.00K 10-Q · filed 2022-11-10 | |||
| 2020-12-31 | $31.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $84.00K 10-K · filed 2022-03-17 | ||
| 2020-09-30 | $53.00K 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |